About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
BOARD MEETINGS
Board
Meetings
Glaxosmithkline Pharmaceuticals Ltd.
From Date
:
To Date
:
Source Date
Board Meeting Date
Details
24-Oct-2024
29-Oct-2024
Interim Dividend & Quarterly Results
18-Jul-2024
02-Aug-2024
Quarterly Results
19-Apr-2024
17-May-2024
Audited Results & Final Dividend
04-Jan-2024
12-Feb-2024
Quarterly Results
04-Oct-2023
09-Nov-2023
Quarterly Results
30-Jun-2023
26-Jul-2023
Quarterly Results
03-May-2023
17-May-2023
Final Dividend & Audited Results
11-Jan-2023
07-Feb-2023
Quarterly Results
31-Oct-2022
11-Nov-2022
Quarterly Results
28-Jun-2022
25-Jul-2022
Quarterly Results
02-May-2022
16-May-2022
Audited Results & Dividend
28-Dec-2021
07-Feb-2022
Quarterly Results
27-Sep-2021
29-Oct-2021
Quarterly Results
06-Jul-2021
26-Jul-2021
Quarterly Results
03-May-2021
18-May-2021
Dividend & Audited Results
07-Jan-2021
05-Feb-2021
Quarterly Results
28-Sep-2020
28-Oct-2020
Quarterly Results
01-Jul-2020
29-Jul-2020
Quarterly Results
11-May-2020
18-May-2020
Final Dividend & Audited Results
27-Dec-2019
03-Feb-2020
GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2020 ,inter alia, to consider and approve Pursuant to clause 33 of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR), this is to inform you that a meeting of the Board of Directors of our Company will be held on Monday, 3rd February 2020, inter-alia, to consider approval of Un-audited financial results for the quarter and nine months ended 31st December 2019
Page
1
of
5
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.